<div id="readability-page-1"><div> SHANGHAI, April 1, 2026 /PRNewswire/ -- MedJ, China's leading medical media platform, today officially launched its dedicated International Platform: a first-of-its-kind authoritative English-language hub delivering real-time, contextualized insights into China's fast-evolving healthcare and biomedical landscape for clinicians, researchers, and industry stakeholders worldwide. <img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2947042/image.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="400" height="225" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2947042/image.jpg"/> The launch comes as China's global influence in biomedical research reaches unprecedented heights. The 2025 NCS Hospital Index, a bibliometric ranking from the editorial teams of Nature, Cell, and Science (collectively NCS), found 41 hospitals from Chinese mainland ranked in the global top 100 for 2025 publications in the three flagship journals and their high-impact sub-journals. This figure outpaced the U.S. (29 hospitals) to claim the No.1 global spot, underscoring the rising authority of Chinese medical institutions on the world's top academic stage.A trusted leader in China's medical media for over a decade, MedJ serves 3 million registered healthcare professionals, reaches 10 million subscribers, and partners with 20,000+ leading medical experts and 10,000+ hospitals nationwide. Its new International Platform eliminates longstanding barriers for global peers: fragmented information sources, language gaps, and missing critical context around China's medical advances.The platform launches with four core editorial sections:<ul><li>Innovation Therapy: Full-lifecycle updates on novel drugs, devices, and regulatory milestones in China</li><li>Doctors: Exclusive perspectives from China's top clinical and research leaders</li><li>Conferences: Frontline reporting from key global medical congresses</li><li>Webinar: Live, two-way academic exchanges between Chinese and global medical communities</li></ul>As China solidifies its rightful place in global healthcare, MedJ's International Platform stands as an open, inclusive gateway for cross-border collaboration. All the critical insights you need, in one centralized destination.Visit [MedJ.cn] to explore.Contact: MedJPhone: +86 21 58545118Mail: medjservice@medj.cn <img src="https://imageproxy.pbkrs.com/https://edge.prnewswire.com/c/img/favicon.png/query-c2Q9MjAyNi0wNC0wMSZzbj1DTjIzNTA1?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="16" height="16" original-src="https://imageproxy.pbkrs.com/https://edge.prnewswire.com/c/img/favicon.png/query-c2Q9MjAyNi0wNC0wMSZzbj1DTjIzNTA1"/> View original content to download multimedia:https://www.prnewswire.com/news-releases/medj-unveils-international-platform-your-trusted-gateway-to-chinas-fast-growing-biomedical-landscape-302730775.htmlSOURCE MedJ</div></div>

科創醫藥ETF工銀

南方恆生生物科技ETF(QDII)

天順股份

MedJ，作為中國領先的醫療媒體平台，推出了其國際平台，這是一個提供中國醫療和生物醫學領域實時洞察的英語中心。該舉措旨在為全球臨牀醫生和研究人員彌補信息差距，突顯中國在生物醫學研究中日益增長的影響力，正如其在 2025 年 NCS 醫院指數中的頂級排名所示。該平台設有創新療法、專家觀點、會議報道和網絡研討會等板塊，促進醫療領域的跨境合作

MedJ Unveils International Platform: Your Trusted Gateway to China's Fast-Growing Biomedical Landscape

MorningStar

易方達中證生物科技主題ETF

方正富邦中證醫藥及醫療器械創新ETF

醫療器械ETF永贏

創新藥

天弘國證生物醫藥ETF

生物科技ETF基金

平安中證醫療創新ETF

博時恆生醫療保健(QDII-ETF)

華安恆生生物科技ETF

博時恆生港股通創新藥精選ETF

招商中證全指醫療器械ETF

招商中證生物科技主題ETF

國泰中證生物醫藥ETF

華夏中證生物科技主題ETF

廣發中證香港創新藥(QDII-ETF)

開普檢測

富國恆生港股通創新藥及醫療保健ETF

MedJ 推出國際平台：您可信賴的通往中國快速發展的生物醫學領域的門户